Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II S-1 + ramucirumab in elderly advanced/recurrent gastric cancer (KSCC1701)
jRCTs071180066Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Primary endpoint: 1-year overall survival rate. Started Sep 2017; status: completed.
02
Drugs
tegafurramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs071180066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180066.